Biomatz
Biomatz develops microbiome-based therapeutics that restore and modulate gut communities to improve health outcomes. The company uses an AI-driven platform (B-ATZ) to design defined, cooperative multi-strain consortia and identify live biotherapeutic product candidates. Its core technology combines microbiome profiling, computational modeling, and strain isolation to engineer reproducible defined LBPs for pharmaceutical, nutraceutical, and functional food applications. Biomatz operates as a B2B biotech, partnering with drug developers and health-product manufacturers. The platform targets clinical and commercial translation across gut-health markets.
Biomatz
Biomatz develops microbiome-based therapeutics that restore and modulate gut communities to improve health outcomes. The company uses an AI-driven platform (B-ATZ) to design defined, cooperative multi-strain consortia and identify live biotherapeutic product candidates. Its core technology combines microbiome profiling, computational modeling, and strain isolation to engineer reproducible defined LBPs for pharmaceutical, nutraceutical, and functional food applications. Biomatz operates as a B2B biotech, partnering with drug developers and health-product manufacturers. The platform targets clinical and commercial translation across gut-health markets.